Navigation Links
ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross

PHILADELPHIA and LYON, France, Jan. 13 /PRNewswire-USNewswire/ -- ERYtech Pharma, French Biotechnology Company, and the Penn Jersey Region of American Red Cross are pleased to announce the signature of an agreement concerning the GMP clinical batches production of ERYtech Pharma's products in the United States.



ERYtech Pharma's co-founder and COO, Pierre-Olivier Goineau says, "this agreement allows ERYtech Pharma to be industrially present in the United States; it is an important step for the development of our products."

"This partnership enables the American Red Cross to show patients and donors that we are committed to providing the best services available," says Brigid O'Neill-LaGier, Chief Executive Officer of the American Red Cross Penn-Jersey Blood Services Region.

ERYtech Pharma's Co-Founder and CEO, Yann Godfrin concludes, "We are pleased to have reached this agreement and we think already to other projects of partnership with the American Red Cross for the development of our products."

About ERYtech Pharma

ERYtech Pharma is a leading biotechnology company developing next generation medicinal products making a huge positive impact on the lives of patients with serious unmet clinical needs.

A pioneer in the encapsulation of therapeutic molecules inside red blood cells, it is developing a pipeline of innovative therapeutics in orphan indications or underserved subpopulation of high risk patient's through its proprietary technology of entrapment and in-depth exploration of red cell physiologic properties.

ERYtech is focused in the fields of Haematology, Oncology and Metabolic Diseases. ERYtech Pharma's most advanced product, GRASPA(R), has completed a Phase II clinical trial in leukaemia and is currently being evaluated in the indication of several solid tumours. Beyond GRASPA(R), ERYtech has several investigational compounds addressing specific unmet clinical needs through enhanced efficacy, better compliance, reduced dosage or increased safety profile.

SOURCE American Red Cross, Penn-Jersey Region; ERYtech Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
(Date:11/30/2015)... - BioAmber Inc. (NYSE: BIOA ), a leader in renewable ... Act on Climate Pledge, alongside more than 140 companies from ... Administration to demonstrate an ongoing commitment to climate action and ... Paris climate negotiations. ... . --> BioAmber uses biotechnology to convert ...
(Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, a ... chemistry professor Jan Halámek, is taking crime scene ...   -->   ... --> --> ... have discovered a straightforward concept for identifying whether ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... new globally touring exhibition Jurassic World: The Exhibition, opening in March 2016 at ... embark on a worldwide tour including several North American tour dates. The Exhibition ...
Breaking Biology Technology:
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
Breaking Biology News(10 mins):